# Biogen (BIIB) Q3 2026 earnings

Results filed 2026-10-28 for the quarter ended 2026-09-30. Source page: https://earnings.opennash.com/companies/biib/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/0000875045-26-000094-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Biogen's first full quarter with Apellis' eye and kidney drugs pushed growth products to 63% of core pharmaceutical revenue, ahead of December Phase 3 lupus readouts.

Biogen's growth products, led by SPINRAZA high-dose conversions, LEQEMBI and the newly acquired SYFOVRE and EMPAVELI, are now the center of the business while legacy multiple sclerosis drugs decline. LEQEMBI's subcutaneous autoinjector is drawing prescribers who never wrote an Alzheimer's antibody before. Management says Apellis integration is going faster than planned and that the company can now grow even without its pipeline.
Next, Biogen is moving into new disease markets: litifilimab in lupus (first Phase 3 data in early December), felzartamab in antibody-mediated rejection and IgAN, and zorevunersen in Dravet syndrome. It is also building a broader early-stage pipeline. The tension is that several Phase 3 outcomes arrive within a year, while new specialist sales teams, new market creation and debt repayment have to be funded and digested.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenue | $2.8 billion | up 11% from a year ago | GAAP |
| Net (loss) income attributable to Biogen | $(20.6) |  | GAAP |
| Diluted EPS | $(0.14) | down 104% from a year ago | GAAP |
| Diluted EPS | $2.62 | down 46% from a year ago | non-GAAP |
| Net cash flow from operations | approximately $641 million |  | GAAP |
| Free cash flow | approximately $600 million |  | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Growth Portfolio | $1.26 billion | up 49% year over year |
| SPINRAZA | $461 | up 23% |
| LEQEMBI (global in-market sales recorded by Eisai) | $202 | up 67% |
| SYFOVRE | $191 | up 27% |
| SKYCLARYS | $178 | up 34% |
| EMPAVELI | $52 | up 92% |
| VUMERITY | $192 | down 11% |
| ZURZUVAE | $84 | up 53% |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Non-GAAP diluted EPS (reported guidance) | full year 2026 | $12.20 to $13.00 |
| Combined non-GAAP R&D and SG&A expense | full year 2026 | approximately $4.95 billion |
| Impact of acquired IPR&D, upfront and milestone charges on EPS | full year 2026 | ~($3.20) |
| Acquired IPR&D expense | fourth quarter of 2026 | approximately $50 million |

## Key takeaways

1. **Apellis integration is ahead of plan** SYFOVRE and EMPAVELI contributed $243 million in their first full quarter, and management says the deal is roughly neutral on an operating basis. It still expects at least $250 million of run-rate synergies by the end of 2027.
2. **SPINRAZA high-dose conversion is pulling demand forward** 70% of 12 mg patients have a start form submitted and 50% have been dosed. One-time transition doses boosted Q3, so management expects a smaller gain in Q4 and fewer such patients next year.
3. **LEQEMBI autoinjector is reaching new prescribers** Management says the subcutaneous autoinjector is outpacing the LEQEMBI IV launch by three and a half times, and is drawing writers who never prescribed an anti-amyloid antibody. Reimbursement is gating uptake; at least 50% of covered lives are expected to have Part D coverage.
4. **Lupus is the next big market bet** Two Phase 3 litifilimab SLE readouts are due in the first half of December, with CLE data in the first half of 2027. Biogen argues lupus is under-treated because physicians hold back biologics, and that it can expand the market as it did in MS.
5. **Commercial footprint is widening beyond neurology** Teams now call on retina specialists, nephrologists, transplant centers and soon dermatologists and rheumatologists. Management says it will limit further large deals and favor early-stage assets to avoid overextending.

## Analyst Q&A

- [0:25:35] Phil Nadeau, TD Cowen: How confident is Biogen in the Phase 3 litifilimab SLE trials, and how do their designs differ from Phase 2? Answer: Priya Singal said lupus is heterogeneous, that steroid tapering and background-medication control are built in, and that both readouts come in the first half of December.
- [0:26:43] Chris Schott, JPMorgan: If AMR data are positive, how fast will felzartamab's market develop and ramp, and is the Street sizing it correctly? Answer: Alicia Alimo cited about 11,000 AMR patients treated at known transplant centers, a medical team that has visited 100 centers to get on protocols, and pricing that reflects value, with MVI adding about 30%.
- [0:31:21] Brian Abrams, RBC Capital Markets: How do baseline characteristics, especially interferon gene signature, in TOPAZ-1 and TOPAZ-2 compare with the Phase 2 study? Answer: Priya Singal said no baseline differences are known and the data will be examined once available.
- [0:32:28] Umar Rafat, Evercore: Given the Phase 2 SRI-4 result was driven by one component, what does that mean for Phase 3, and can data be pooled? Answer: Priya Singal said SRI-4 is the right endpoint for skin and joints and that pooling will depend on the data and regulator discussions.
- [0:34:02] Salveen Richter, Goldman Sachs: How much of SYFOVRE's injection growth comes from less free drug versus demand, and what is resonating on discontinuations? Answer: Alicia Alimo credited improved physician sentiment and broader prescribing, said month-one discontinuation is high because patients are not told what to expect, and said education and a 2027 DTC campaign are planned.
- [0:37:32] Michael Yee, UBS: How confident is Biogen in the cutaneous lupus readout compared with the systemic lupus trials? Answer: Priya Singal declined to state confidence, noting activity in both forms in Phase 2 and that SLE is more heterogeneous.
- [0:39:15] Alex Hammond, Wolfe Research: What is U.S. SPINRAZA high-dose conversion and where will it settle, and what does it imply for salanersen? Answer: Alicia Alimo said 70% of 12 mg patients have start forms and 50% are dosed, so fewer transition doses will benefit next year, and patients already ask about salanersen.
- [0:42:19] Analyst, Stifel: What supports premium pricing for zorevunersen outside the U.S., and how important is a cognition effect in Phase 3? Answer: An executive said there is an opportunity to reprice the market, with an addressable market of at least $1 billion outside the U.S. if Phase 2 results replicate.
- [0:43:38] Analyst, BMO Capital Markets: What is field feedback on LEQEMBI iClick and how can the market expand next year? Answer: Alicia Alimo said iClick is outpacing the IV launch, is drawing first-time antibody writers, and Part D coverage should exceed 50% in January.
- [0:47:13] Jeff Meacham, Citi: How will Biogen balance capital between internal R&D, commercial investment and business development? Answer: Christopher Viehbacher said it will keep investing in commercial and R&D while watching margins, focus business development on early-stage assets, and avoid overextending.
- [0:51:45] David Anselm, Piper Sandler: How does Biogen size the cutaneous lupus opportunity relative to SLE? Answer: Alicia Alimo said they are separate markets, with about 300,000 CLE patients and under 5% treated, and that dermatologists need to be encouraged to treat early.
- [0:55:28] Daniel Brill, Truist Securities: Is Biogen changing the felzartamab IgAN trial design given the FDA's openness to a one-year eGFR endpoint? Answer: Priya Singal said Biogen is already switching the primary endpoint to eGFR and sees the drug-holiday option as a key differentiator.
- [0:57:19] Analyst, Wells Fargo: Why does the guidance imply a sharp sequential drop in fourth-quarter revenue? Answer: Robin Kramer said Q3 pulled forward SPINRAZA conversions and inventory, and that the guidance change mainly reflects Apellis performance and faster synergies.
- [0:59:15] Andrew Tai, Jefferies: If both litifilimab and dapirolizumab succeed in SLE, how would they be positioned against each other and competitors? Answer: Alicia Alimo said two shots on goal provide differentiation, and success will depend on data and on addressing why physicians and patients hold back on biologics.
- [1:01:09] Mark Goodman, Leerink Partners: What is driving SKYCLARYS growth in the U.S. and in individual markets abroad? Answer: Alicia Alimo cited AI-assisted patient finding, lower discontinuation and a pediatric opportunity, and Robin Kramer said ex-U.S. growth comes from new country launches, including Brazil.

## Questions

**What drove Biogen's growth portfolio this quarter?** Revenue from the growth products rose 49%, helped by the first full quarter of Apellis' SYFOVRE and EMPAVELI and by SPINRAZA high-dose conversions. Growth products now make up 63% of core pharmaceutical revenue.
**How is LEQEMBI's subcutaneous autoinjector doing?** Management says iClick is outpacing the IV launch by three and a half times and is being written by physicians new to Alzheimer's antibodies. Uptake is gated by reimbursement, with at least 50% of covered lives expected to have coverage in 2027.
**What are the next pipeline catalysts?** Topline data from both Phase 3 litifilimab SLE studies are expected in the first half of December 2026. Litifilimab in CLE and felzartamab in AMR follow in the first half of 2027, and zorevunersen in Dravet syndrome in the third quarter of 2027.
**How is the Apellis deal performing?** SYFOVRE and EMPAVELI contributed $243 million, and management says the deal is roughly neutral on an operating basis. It expects to be accretive to non-GAAP EPS in 2027 with at least $250 million of run-rate synergies by the end of 2027.
**Where is Biogen's legacy multiple sclerosis business under pressure?** MS product revenue fell 13%, and VUMERITY fell 11% as Part D payers tightened formularies. TYSABRI held up, supported by the subcutaneous formulation in Europe.

## Transcript

Machine-generated from https://www.youtube.com/watch?v=sBK0pNE068k


**Cynthia (Operator)** [0:00:00]
Good morning, my name is Cynthia and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen 3rd Quarter 2026 Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star 1 on your telephone keypad. Please limit yourself to one question to allow other participants time for questions.
If you require any further follow-up, you may press star 1 again to rejoin the queue. Today's conference is being recorded. Thank you. I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.

**Tim Power (Investor Relations)** [0:00:47]
Thanks, Cynthia. Good morning, everybody. Welcome to Biogen's third quarter 2026 earnings call. During this call, we will make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements.
We provide you a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results, as well as reconciliations between GAAP and non-GAAP results discussed on this call, can be found in the Investors section of Biogen .com. We've also posted the slides to our website that we'll use during the call. On today's call, I'm joined by our President and Chief Executive Officer, Chris V.
Bakker, Dr. Priya Singal, Head of Development, Robin Kramer, our Chief Financial Officer. Alicia Alimo, President of North America, is also available for the Q &A section of the call. We'll make some opening comments and we'll move to the Q &A session. And to allow us to get through as many questions as possible, we'll ask you to kindly limit yourself to just one question. And I'll now hand the call over to Chris.

**Christopher A. Viehbacher (CEO)** [0:01:48]
Thank you, Tim. Good morning, everybody.
Very strong quarter this morning. It's actually one of those quarters where the numbers almost just speak for themselves. Total revenue grew 11 % year over year. Of course, that's not all organic. That was significantly benefited from the acquisition of Apellis. But I'd also say that I think the acquisition and the integration of Apellis has gone even better than expected. The integration team has, I think, been able to identify and eliminate cost synergies faster than we thought.
Alicia is here, and I have to give Alicia a lot of credit for her leadership in really ensuring that the PELOS team has felt welcome within Biogen. And I think really the most credit goes to the people from Appelos who have joined Biogen, placed their faith in Biogen, and have been able to look past the inevitable distraction that comes with an integration and really focus on our customers, the healthcare professionals and patients that we serve. So as I look at it, obviously Appelos has certainly helped us.
You know, our industry has embraced bolt-on acquisitions over the years, but one of the things I've learned is if you're going to do a bolt-on, you have to bolt on to something solid. And one of the things that we have been working on at Biogen over the last several years is really to improve our cost base, but also to really launch our growth products and get those performing on a top level. And that's important because when you do an acquisition, there is an inevitable amount of distraction.
And if you've got a team that's already performing well, then it can not only find the time to embrace a new team joining the company, but the new team joining also finds a culture of energy, of positive spirit that becomes infectious in some ways. And so I think we've really realized a synergy between the folks from Apellis who joined the Biogen teams. They've come together. And when I look at SYFOVRE and Paveli, you can see 37 % year-over-year growth of 243 million.
That's already on a run rate of $1 billion. And we're on track to realize 250 million of run rate synergies by the end of 2027. And in fact, you'll see from the guidance that we put out, and Robin will detail this more, but we've reduced our estimate of what the dilution will be in this first year of acquisition. In fact, most of the dilution will be really from the financing. At an operating level, the dilution is already pretty much negligible.
If I look at Biden's own growth portfolio, $1.26 billion, that's 50 % year-over-year growth, that's now almost getting to two-thirds of our core pharmaceutical revenue in Q3. And so this is where the story has been that we've obviously had a legacy portfolio that continues to be resilient, but the future is really with the growth products. And so if I go to the next slide, we've really got three key priorities here. One is to continue to grow that commercial portfolio.
And as I say, the 50 % growth is extremely strong. And we expect to return to top-line growth in 2026. I will say that the resilience of the legacy MS portfolio, I've said this in the past, it's not by accident. Biogen has a unique patient services team. I think we have built strong relationships with key physicians and have earned the trust of a lot of patients. And I think that is a capability that's going to be extremely important as we turn to the next priority, which is this multi-year registrational data flow.
The first point I'd make on that is, you know, given the Apellis acquisition, we now think that the company can grow even without the pipeline. So as the pipeline starts to read out, and, you know, I think the first readout will be now just weeks away, We think we can be launching products, assuming that clinical trial results are positive. We'll be able to launch products on top of a growing base. The other I would say is, you know, there are going to be a number of areas where we're still in breakthrough.
You know, AMR is a market, for instance, that doesn't exist. MBI is a market that doesn't exist. In fact, a lot of education is needed. but we're already seeing high levels of awareness on those. We do know how to create and build markets. We're not a company that is just used to going in and finding an existing market and just taking market share. That will also be important in lupus and Alicia can provide a lot more insight here but when you look at the lupus market, is it a fraction of what the MS market is?
And there's no real good reason for that. We have found some insights into that. One is that patients will be expected to be on treatment for many, many years. And with only two approved biologics, physicians tend to conserve those biologics until a patient progresses. And we're certainly seeing an awful lot of feedback from the market that if another biologic does get approved, that there would be an enhanced willingness to actually use biologics in an earlier stage.
And I go back to how Biogen has built its MS business and have been able to retain it in the face of some pretty fierce competition. And I think a lot of those capabilities and skills will really enable us to think about how we can actually develop the lupus market way beyond where it is today. And just, you know, really in the next 18 months, we've got phase 3 readouts expected, you know, not only in SLE, but we've got cutaneous lupus, we've got AMR, and our partners at Stoke, we expect to be reporting on Zorva, Nursin, and Dravet syndrome.
And then the third priority, the third priority I think is one of the most important and often most neglected areas of our industry. And this is an area where we at top leadership at Biogen are spending a lot of our time. Because it's in research and early development that you are building the future of your company. And we were not necessarily very good with that. We had gone three years without a single IND. Under the leadership of Jane Grogan and in partnership with Priya Single, They have done a radical overhaul of the whole research and early development area.
We now have six new programs expected with the three NMEs. We've already had five INDs this year. As Priya will tell you, Biogen in its 48 years of history has never had five INDs in a single year. And our ambition is over the next few years to have at least 20 programs in early stage development. And this is a big shift in how we operate because Biogen historically has looked at things on an asset by asset basis.
And we are now really thinking about portfolios of opportunities. How do we balance the risk? How do we balance that with franchise development and breakthrough medicines along with best in class and not always just first in class medicines. So this is an area where we're already planning for the future. You know, in this business, the day you launch a new product is the day you should be thinking about what product is going to succeed in. And so those are the three areas.
I think it's exciting. The future of Biogen is before us. And with that, I'll turn it over to Priya who can give us a little bit more insight to the excitement awaiting us.

**Priya Singal (Executive)** [0:10:38]
Thank you, Chris, and good morning, everyone. Over the past few years, you have heard us talk about the pipeline transformation, as Chris just mentioned. I'd like to take a few minutes to remind you of where we are today. Our new Biogen strategy remains centered around delivering a path to sustainable growth over the long term, and we are pleased by the progress we've made in delivering on that goal.
This is an exciting time for Biogen, and today, as a result of this strategy, we have built one of the strongest and most diversified late-stage pipelines in Biogen's history, with the potential to address significant unmet needs across neurology, immunology, and kidney disease. We showed you this slide last quarter, and as we previously communicated, due to strong execution by our teams and positive enrollment momentum, we were able to pull forward the Topaz II SLE readout for litafilumab and the Transcend readout for felzadumab in AMR.
So reflected on the slide, I'm pleased that our upcoming registrational readout cycle remains on track, starting with our planned disclosure of the two Phase III SLE studies for litafilumab in the first half of December. As we turn beyond that, we expect CLE data from litafilumab, as well as AMR data from salzadumab, followed by a readout from Zorobanorsan in Rave syndrome, expected in the third quarter of next year. Beyond that, we expect to continue our multi-year cycle of important registrational data flow through the end of the decade.
Each of these upcoming catalysts has the potential to meaningfully shape Viagin's next phase of growth, while most importantly, creating the possibility of new treatment options for patients. As Chris also mentioned, we have remained focused on building and rebuilding our early stage pipeline. We will continue to focus on our portfolio construction and evaluate internal and external innovation on a program-by-program basis with a scientific and disciplined approach. Looking to the future, I'm excited about how our transform pipeline has the potential to benefit patients across disease areas, and I look forward to providing updates as we move forward.
With that, I would now like to turn the call over to Robin for the financial update.

**Robin Kramer (CFO)** [0:13:24]
Thank you. Thank you, Priya. I'm pleased to provide our update on another strong quarterly financial performance. Our results reflect the continued momentum in our commercial portfolio that we've seen throughout this year, and Q3 marks the first full quarter with SYFOVRE and Epivelli in our growth portfolio. Total third quarter core pharmaceutical revenue was $2 billion, up 18 % year-over-year and 9 % quarter-over-quarter.
This was driven by the continued strong performance of our growth portfolio, which generated a approximately $1.3 billion of revenue in the quarter, up 49 % year-over-year and 19 % quarter-over-quarter. In addition, SYFOVRE and Epivelli together contributed $243 million in Q3 2026. That portfolio now represents approximately 63 % of our total core pharmaceutical revenue. This quarter's results demonstrate continued strong commercial execution and emphasizes the significant progress we've made in our portfolio transition.
Let me now take you through key highlights from our core pharmaceutical product performance in the third quarter. First, the growth portfolio. Spinraza revenue was $461 million, up 23 % year-over-year and 15 % quarter-over-quarter. This performance was driven primarily by rapid patient conversion to the high-dose regimen, with the quarter reflecting a meaningful revenue tailwind associated with the one-time transition doses for patients converting from low-dose Benraza. As the conversion cohort matures and dosing patterns normalize, especially in the U .S., we expect global Q4 revenue to be up approximately a mid-single-digit percentage versus the fourth quarter of 2025.
We are pleased with the rapid pace of conversion to high dose, which has exceeded our expectations. We believe the enthusiasm from patient and prescriber communities is encouraging for the opportunity for Sal and Urson. Vumerity revenue was $192 million, down 11 % year-over-year and 2 % quarter-over-quarter. Revenue in the quarter was impacted by a shift in the Part D landscape. where payers have adopted a tighter approach to formulary management, a broader macro trend that we are seeing across the industry.
We expect to continue to see this formulary dynamic affect Part D drugs like Vumerity this year. As a result, we expect fourth quarter revenue for Vumerity to be roughly flat sequentially or up approximately a mid-single digit percentage versus the fourth quarter of 2025. Beyond that, we believe these dynamics establish a new base from which Vimerity can grow. LEQEMBI in-market revenue was $202 million, up 67 % year-over-year and 10 % quarter-over-quarter, as we've seen a continuation of market growth and key geographies.
We are in the early phases of the iClick launch and have started to see some uptake in the U .S. Patients can currently access reimbursement for iClick through a medical exception process. We expect uptake to be gated by broader reimbursement. With coverage plans now being finalized, we're encouraged that at least 50 % of covered lives are expected to have coverage in both the initiation and maintenance administration starting in 2027 which should support iClick adoption as we move into the next year.
SKYCLARYS saw patient demand growth both in the US and ex-US with revenue of $178 million representing 34% growth year-over-year and 6% quarter-over-quarter. Third quarter performance also reflects favorable inventory dynamics including an inventory build of approximately $12 million that we expect to be drawn down in Q4. For our legacy MS portfolio, TYSABRI revenue of $437 million was up 1 % year-over-year. US revenue benefited from year-over-year inventory dynamics while the European business continues to show stability driven by the subcutaneous formulation.
We have been pleased that TYSABRI has been able to demonstrate meaningful resilience in light of a competitive MS market. Let me now turn to SyFovry and EMPAVELI. Q3 represents the first full quarter of operations following the close of the Apellis acquisition in May and the integration has continued to progress well with both SyFovry and EMPAVELI having another strong performance this quarter. SyFovry revenue was $191 $1 million, up 27% year-over-year, driven by continued commercial injection volume growth, which was up 18% year-over-year and 7% quarter-over-quarter.
The third quarter has the strongest commercial injection quarter since launch, and SIFO recontinues to demonstrate market leadership and geographic atrophy. I would note that third quarter results include approximately an $11 million inventory bill, which we expect to be drawn down in Q4. Looking forward to Q4, we also anticipate our price will normalize back to historic levels following a one-time price benefit related to the launch of the COPAC. Despite this, we expect fourth quarter revenue to be up approximately a mid-single-digit percentage versus the $155 million reported by Apellis in the fourth quarter of 2025.
Ampavelli revenue was $52 million, which was up 11 % quarter over quarter, driven by strong demand for the nephrology indications, C3G, and primary ICMPGN. Sequential demand for PNH remains stable, and with this market being highly competitive, we are hiring a dedicated sales force to drive PNH penetration. In light of this commercial performance and the pace of integration synergy capture, we believe this transaction is now roughly neutral on an operating basis and we expect the transaction to be less diluted in 2026.
We continue to expect the transaction to be accretive to non-GAAP diluted EPS in 2027, generating at least $250 million of run rate synergies by the end of 2027. Now turning to financial highlights for the quarter. Total revenue was $2.8 billion, up 11 % year over year. This marks an acceleration in our top-line growth trajectory, supported by the impact of the Apellis acquisition on our overall revenue profile. Non-GAP core OPEX, or combined R &D and SG &A expense, increased 27 % year-over-year.
This increase primarily reflects the expected impact of the PELUS operating expenses, as well as continued investment in our Phase III programs, so tofilimab and SLE and CLE, filzardimab and AMR, servanursin and Dravet syndrome, and salinursin and SMA, as well as support for the U .S. and international product launches and pre-launch activities for our late-stage pipeline assets. As we previously announced, we recorded $284 million of acquired IPR &D and milestone charges in Q3 2026, largely associated with our Race Era acquisition.
This reflects an approximately $1.70 impact to non-GAAT diluted EPS and approximately $1.65 impact to GAP diluted EPS. GAP EPS was a loss of $0.14 impacted by the IPR &D and milestone charges I noted, higher amortization costs associated with the acquired inventory fair value step-up adjustment for SKYCLARYS from the Riata transaction, and Saipovri and Epivelli from the Apellis transaction, as well as restructuring costs related to the Apellis acquisition. Now, turning to cash flow and the balance sheet.
We continue to generate strong cash flow with $600 million of free cash flow generated in third quarter of 2026. We exited the quarter with $1.3 billion of cash and $6.4 billion of net debt. During the third quarter, we repaid $400 million of the term loans related to the appellas acquisition. We have now repaid $600 million in total and continue to expect to repay the remaining $1.4 billion of term loans by the end of 2027.
Now turning to guidance. As you heard this morning, we've continued the good business momentum in the third quarter and importantly remain on track to deliver top-line growth for the first time in several years. We have been encouraged by the faster synergy capture from the Apellis acquisition, resulting in favorability in the expected 2026 dilution. We are pleased to be raising the lower end of our reported full year 2026 non-GAAP diluted EPS range to between $12.20 and $13.
The business performance from the third quarters also reflects strength from execution, including acceleration of revenue from the pace of conversion from the high dose regimen of Spinraza and Q3. We also expect some typical Q4 phasing as well as SKYCLARYS inventory dynamics I spoke about a few moments ago, and continue to expect lower contract manufacturing revenue in the fourth quarter due to timing of batch commitments. Reflecting on where we are today in relation to core operating expenses, we are pleased to have captured some of the appellate synergies faster than expected.
Our core OPEX guidance reflects the typical seasonally higher core OPEX spend in the fourth quarter and includes the planned investments to support the advancement of our late stage pipeline and pre-launch activities. We also now expect approximately $50 million of acquired IPR &D in the fourth quarter. We will continue to balance this investment as well as investing to support the commercial success of the growth portfolio while ensuring a keen focus remains on profitability. Please be sure to review this slide as well as our press release for other important full year 2026 guidance assumptions.
In closing, Q3 2026 was another strong quarter and a continuation of the momentum we've seen this year. Our growth portfolio has now exceeded the legacy MS portfolio for multiple consecutive of quarters and the first full quarter of Saibovri and Empevele demonstrates the strategic and financial rationale for the Apellis acquisition. As we strengthen our portfolio, we are on track to grow our business next year as we also focus on important data reads from our pipeline to further strengthen our long-term growth potential.
With that, I would like to pass the call back to Tim to open us up for questions.

**Tim Power (Investor Relations)** [0:25:12]
Thanks, Robin. Can we go to our first question, please, Cynthia?

**Cynthia (Operator)** [0:25:16]
Thank you. If you would like to ask a question, please press star 1 on your telephone keypad. As a reminder, please limit yourself to one question. If you require any further follow-up, you may press star 1 again to rejoin the queue. Your first question comes from the line of Phil Nadeau with TD Cowan.

**Phil Nadeau (TD Cowen)** [0:25:35]
Good morning. Thanks for taking our question and congrats on the solid quarter. We wanted to ask about the upcoming lidophilumab data in SLE. I think that is now becoming a focus of investors. Can Ayjin discuss its confidence that those phase three trials will succeed and maybe work into that, the differences in the phase three design versus phase two?

**Tim Power (Investor Relations)** [0:25:55]
Dr. Ria, do you want to take that one? Dr. Ria Nguyen - Sure. Thanks, Phil. So, I think just stepping back, you know, we recognize and acknowledge lupus is a very heterogeneous disease.
We studied past trials. and we've extensively put several strategies in place to optimize the outcomes and I've discussed those in the past and I think just to name a few you know the steroid tapering control of background standard of care meds so I don't really have anything new to add to those strategies we remain very close now to data readouts both of them being disclosed in the first part of first half of December so I'll just stop there and we look forward to seeing the data as well.
Thanks, Priya. Let's go to the next question, please.

**Cynthia (Operator)** [0:26:46]
Your next question comes from the line of Chris Schott with JP Morgan.

**Chris Schott (JPMorgan)** [0:26:50]
Great. Thanks so much. Just a question on Fulzart and AB. I know you mentioned this a bit in the open remarks, but assuming positive data in AMR, can you talk a little bit about how you're thinking about the rate of market development and the ramp of the product. And again, maybe since you spent more time in this market, just comment maybe a bit on how the street's modeling this.
Do you think the street's kind of getting this right in terms of how big of an opportunity this could be? Thanks so much.

**Alicia Alimo (Executive)** [0:27:21]
Hello, Chris. This is Alicia. I'll take your question. So we've been spending a lot of time looking at AMR, and I also think we've been looking a lot at MVI as well, which I'll touch on briefly. But for AMR, and actually just recently at ASN, the team really spoke to many of the transplant physicians that would potentially be treating patients for this disease.
And I have to say that they were very enthusiastic about fellows of scientific MOA. And it really was incredibly positive conversations. When you look at AMR, we believe there's around 11,000 patients. And you have to also remember that not all of those patients will go on products. Several of those patients will already be too late in their progression, but there's a very large cohort that will. Now, currently, AMR will be treated in transplant centers, and transplant NEPs see themselves as stewards of the graft.
So the interesting thing about the space is we know exactly who will be treating the patients. It's about getting the patients in there. The one thing that we've learned from Empivelli, now that Empivelli has been working with transplant NESS is that in a lot of these centers, you have to be on protocol. Now, I mentioned protocol because protocols can take time, which is why we've already hired a medical team that has already visited 100 transplant centers, and they're already looking at how you get on the protocol as quickly as possible once you have an approval.
So when you look at the ramp, you're going to have to know a couple of the months out of the gate. You're going to have some centers that will start right away. You have others that will gradually come on. You're also going to have a bolus of patients that are already sitting in that transplant center. So typically, transplant patients are with the transplant center for approximately a year. They go back to their general nefts. General nefts are actually very good at monitoring for AMR.
They're also pretty good at already referring them into the transplant centers. So that system, though it's not perfect, is already there. So we know that we will already out of the gate, have a good set of patients at launch, and we're already currently working on the second tranche of patients that you would get after you see that bolus. And so when we look at the top 100 centers, like I said, right now it's about educating and understanding the protocols and how quickly we can get on.
And then for general NEPs, it's around how they consistently properly diagnose and do surveillance for AMR and ensuring that they refer them earlier versus later. Now, along with that ramp, obviously, we get a lot of questions about price, and you've probably seen what's been happening in the market with IGAN, but we do believe that pricing will reflect the significant value that Fels is going to have for patients. And when you think about pricing for the product, also keep in mind the dosing of felzartimab.
For example, in AMR, in year one, they will have 12 doses. In year two, they have six and a half doses. So you're also going to see, like what we saw with Spinraza, that first year is where you're going to capture actually quite a bit of value for the patients as they go down to six and a half doses in the second year. In addition to AMR, you have MVI. Now, we view MVI as incremental to AMR rather than a separate commercial market.
And now that we've done more work on it, we can understand that physicians are also looking at MVI. We believe that this gives an additional 30 % on top of that patient population of AMR. So the biggest opportunity for MVI will be for raising more awareness outside of KMEs. Right now, KMDs understand it greatly, but it's currently an underappreciated disease that we have some time to work on, but we've already started those conversations. Thanks very much, Alicia.
Can we go to the next one, please?

**Cynthia (Operator)** [0:31:24]
Your next question comes from the line of Brian Abrams with RBC Capital Markets.

**Brian Abrams (RBC Capital Markets)** [0:31:29]
Hey, good morning. Thanks for taking my question, and congrats on the quarter. Maybe another question for Priya on alitafilumab. lidofilumab. I know you guys have already presented some of this, but can you elaborate a little bit more on how you view the baseline characteristics of patients who enrolled in Topaz 1 and 2 as comparing to the Phase 2 study, in particular with respect to interferon gene signatures?

**Tim Power (Investor Relations)** [0:31:53]
Thanks.

**Priya Singal (Executive)** [0:31:54]
Thanks, Brian. Just stepping back, I think interferon gene signature across the board, but we expect it to be high in SLE patients, and that is what the literature supports as well. And really from a baseline perspective, there aren't any differences that we are aware of in terms of lilac versus Topaz 1 and 2 on interferon gene signature. We'll only know afterwards when we look at the data, and this is areas we'll be examining carefully. Thanks, Priya.
Let's go to the next question, please.

**Cynthia (Operator)** [0:32:31]
Your next question comes from the line of Umar Rafat with Evercore.

**Umar Rafat (Evercore)** [0:32:35]
Hi, guys. Thanks for taking my question. I wanted to focus on the SLE trial as well. Priya, when I look at the Phase II data, one thing that stands out on the SRI-4 endpoint is that the entire delta, this entire separation versus placebo, was driven by sort of one subcomponent, which is LIDI2. Again, I'm sure you're very familiar with that as well.
How are you thinking about the relevance of that finding heading into Phase III? Do you still expect it to be SLID-I2K driving it or additional components as well? And will you be in a position to pool data across both studies by interferon high subgroup if needed? Because there's other companies in the space commenting on that, even in a scenario where one of the trial does not hit stats.

**Priya Singal (Executive)** [0:33:20]
Yeah, thanks, Omar. I think, you know, just stepping back, I think we believe that SRI-4 is the right primary endpoint when we design the trial, given that our focus is on skin and joints.
and how it kind of measures outcomes. So I think from that perspective, we think that's right. Yes, I think we will have the opportunity once we see the data to decide how we might pool and what aspects of these trials should be combined. And I think this will be data dependent and also dependent on conversations and discussions with regulators. So we wait to see the data. And of course, we plan ahead of that, but we wait to see the data now.

**Tim Power (Investor Relations)** [0:34:02]
Go to our next question, please.

**Cynthia (Operator)** [0:34:04]
Your next question comes from the line of Salveen Richter with Goldman Sachs.

**Salveen Richter (Goldman Sachs)** [0:34:09]
Good morning. Thanks for taking my question. Could you speak to how much of an increase in commercial injections for cipher ovaries due to reducing free drug use versus demand? And also, with regard to the education campaigns, as you look to improving the discontinuation rate, maybe help us understand what is resonating with physicians and patients and where the remaining barriers are.

**Alicia Alimo (Executive)** [0:34:36]
Hi, Salvine. This is Alicia. Thank you for the question. The team has done actually a phenomenal job with lowering the free goods on this product, but that's been throughout ever since we did the acquisition. So we identified that as a potential area of improvement before we had even acquired them. The team has done a nice job of that. But when you look at the commercial injection growth, especially year over year, we do tie this to the fact that the Cyphobri team has also done a very nice job on improving the sentiment on treating GA in general and slowing lesion progression.
In fact, I went to one of their large conferences and met with many of the PE firms and with the retina specialists. And the sentiment they say across the board has improved quite a bit and they are now more willing to do more injections. And so these commercial injections are coming from also more HCPs that are coming on board and more depth of prescribing as well. Now I have mentioned before that the discons after that first month of injection is quite high.
We are just now putting into place a lot of those tactics to try and address that. And I have to say that the biggest problem is this. When I talk to a physician or we do patient market research, patients aren't really explained what to expect when they get the injection. And if you compare it to wet AMD, which, by the way, 40 % of GA patients also have wet AMD, they're expecting everything to clear right away.
They don't understand the slowing of progression. So when they get the injection, they feel like, oh, that doesn't work. They don't come back. And so there's an educational piece there that we're putting into place, not only for patients, but even for office staff and also really talking to the physicians. And when you talk to the retina specialist, they don't actually realize that these patients have dropped off at month one. So I do think once the education goes into place, we are going to see quite a nice lift on that when they start educating the patients.
The other part of that is going to be around, I've mentioned this before, you know, now that we have a very strong quarter and not only grew in revenue but also grew in the volume, we believe DTC is going to be a great strategic lever. And we noticed that because, you know, they ran DTC a while ago for SYFOVRE. And actually, the results of it was very good. You saw a direct impact in the patients going in and requesting the product.
And then for whatever reason, they, of course, stopped it. But now that they are in Biogen, we've decided to kick that back up again. We already have a concept. We shared it with Chris. We think it will be a very good DTC and we hope to launch that next year and we do believe will drive even more patients into doctors' offices.

**Tim Power (Investor Relations)** [0:37:24]
Thanks, Alicia. Let's go to the next question, please.

**Cynthia (Operator)** [0:37:26]
Your next question comes from the line of Michael Yee with UBS.

**Michael Yee (UBS)** [0:37:32]
Great. Thank you. Maybe just a question on the cutaneous lupus readout in the first half. Maybe you could just comment, Priya or Chris, on your confidence in that indication and that program versus the systemic indications, which I think people would view as a little bit higher risk, and thinking about either the target, which is different than dapalizumab, for example, and just your overall confidence in that study. I know you're appreciating you're running one study here versus systemic two studies.
So, just wanted to think about how you are framing the cutaneous readout. Thank you.

**Priya Singal (Executive)** [0:38:11]
Yep. Thanks, Michael. I think just stepping back, you know, we believe that both SLE and CLE are high unmet need areas. We also think that the mechanism of action, as we saw from Lilac in phase two, we see that the drug has activity in both forms of the disease. I think just stepping back, it's too close really now and I don't want to speculate, so I'm not going to really talk about confidence.
We know that systemic lupus is generally more heterogeneous. So I think that's the area that I spoke about earlier as well as to what are the strategies we put in to really address the variability that we see. Moving to cutaneous lupus, this is obviously a visible condition, it's easier to kind of visualize and see impact. So, I'll just stop there, but I think overall we believe both are important high unmet needs and we're going to see data in both these indications.
And we have seen data in Phase 2, so we'll wait to see what we get in Phase 3.

**Tim Power (Investor Relations)** [0:39:21]
Thanks, Paya. Let's go to the next one, please.

**Cynthia (Operator)** [0:39:24]
Your next question comes from the line of Alex Hammond with Wolf Research.

**Alex Hammond (Wolfe Research)** [0:39:28]
Thanks for taking the question. So for Spenraza high dose, can you characterize what levels of conversion you see in the United States and at steady state where do you expect this to fall? As a follow-up too, does it give you confidence on the commercial dynamics for salinersin, assuming a positive phase three result I think in 28?

**Alicia Alimo (Executive)** [0:39:50]
Thank you, Alex. This is Alicia. We are really pleased with the performance of Spenraza high dose. In fact, for anyone that looks at the rare disease launch benchmarks, you know, Spinraza 12-MIG used to be the benchmark for the best rare disease launch ever. And now it's actually Spinraza high dose. And we do believe this has now set a new bar also for efficacy. You know, the one thing about this community that is so special is, number one, they know every trial that's coming out.
They know every physician. And when they want something, they ask for it. So a lot of what you're seeing with Spinraza high dose is really coming from the community, pulling it, and asking doctors for it. And not just in the U .S., by the way. I want to say both of the other regions, both Europe and ex-U .S. and Europe, we're seeing similar results across the board with Spinraza high dose. And all of the launches across the board have been successful.
So if you look at our start forms, which is basically the intent to get the prescription for the patient. At the end of Q3, 70 % of the 12 MIG patients now have a start form submitted, which is very high. And we know that 50 % have now been dosed the product. That means that they've pulled forward quite a few of these patients. And clearly, we're not in Q4 yet, but as you can imagine even more of those patients will now land in Q4.
That means for next year, there aren't as many patients that will be getting that one-time benefit of the 90,000 that you're seeing this year with every transition dose. Now, the other thing that we are seeing, and this is also across all regions, is that you're seeing patients come back. So they've been on Spinraza. They went to a competitor, and then we call that a switchback. So we have seen a portion of patients switching back.
We've also seen a portion of patients either being dosed right before their Zolgensma or after Zolgensma. So there's a market there that we will be looking at next year on switchbacks and on new patients that will go beyond the transitions. Now, with that being said, what's our goal with Spinraza high dose? It's to maintain the patients that we currently have, especially as we approach a potential launch of salinersin, which I have to say the community already knows about salinaresin and patients are already asking about it.
So we also believe that that will be a very large commercial opportunity for us if we do get an approval for it.

**Tim Power (Investor Relations)** [0:42:27]
Let's go to our next question, please.

**Cynthia (Operator)** [0:42:29]
Your next question comes from the line of Paul Matisse with Stiefel.

**Analyst** [0:42:34]
Hey, great. Thanks so much for taking my question. I wanted to throw one in on juvenorsin ahead of data next year. Can you talk about the work you've done to garner conviction in pricing that drug at a premium outside of the U .S.
where anti-epileptic medicines are generally not that expensive? And as it relates to the thesis there, how core to that thesis is actually showing a stat-sick effect on cognition in the Phase III Dravet study? Thanks so much.

**Executive** [0:43:04]
Yeah, Paul, I think there is an opportunity to reprice this market, and the real differentiation is the impact on condition, as you said. So, as we, I think we've already talked about that this is an addressable market of at least $1 billion outside the U .S., and, you know, obviously we need to see the phase three results but I think if they replicate the phase two and I do think we have a pretty compelling proposition to take to payers in
Europe

**Tim Power (Investor Relations)** [0:43:38]
yes let's go to the next question please Sophia

**Cynthia (Operator)** [0:43:42]
your next question comes from the line of Evan Siegerman with BMO capital markets

**Analyst** [0:43:47]
hi guys thank you so much for taking my question and always congrats on the the really nice progress I want to touch on LEQEMBI and LEQEMBI iClick just you know given the growth we're seeing there. In the field, what's the feedback from both patients and providers regarding iClick? Is it driving the uptake that you would hope it would have?
And then thinking ahead to next year, what else can you do to expand the market and continue the growth? Thank you so much.

**Alicia Alimo (Executive)** [0:44:17]
Okay. Thank you, Evan. This is Alicia. I'm very excited that you asked about what can be iClick. I think first I would like to address, if you don't mind, Part D, because those are the questions we had quite a bit over the last couple quarters. And if you have been able to look at the published formularies already, you're going to see that Part D, as Robin had also mentioned, we have at least 50 % coverage, which I have to say during this time, especially post-IRA, Part D plans have been quite restrictive.
So we're very pleased with where we are with Part D. Also keep in mind it's an open enrollment right now, so I can't actually tell you the total lives because 30 % are still in flux. So even though we know of 50 % now, we do believe that we will have greater than 50 % going into January of next year, which is better than what we had expected to have for next year. So that is very good news.
Now, when you look at how iClick is performing, I think that what you're going to see is it's really reframing the convenience conversation. And this is actually a critical moment for LEC to become more accessible and easier to start for patients. And in the longer term, which we've said before, we believe iClick is one of the only things that we have that will actually grow the market in general for the entire class. Now, if you look at DDD data, which I know many of you buy, it doesn't have a great capture rate.
It is going to show really astronomical numbers for how they capture it. I'd say, you know, don't look at iClickI for the DDD data. But when you do look at how it's performing in market and you compare it to, let's say, the LEC IV launch or Casimla, iClickI is outpacing the LEC IV launch by three and a half and Casimla by six times. Now, these are early days. And so you are going to see that some of that is going to be, you know, orders going into certain IDNs and maybe some bolus of patients.
However, the interesting thing that we are seeing that we haven't seen before. iClick, of course, the majority you're going to see come from LEQEMBI writers and also dual writers, but we are now seeing writers who have never written an AAT before, never written KISS, never wrote LEC IV. They're writing iClick. And we're also seeing physicians who have only ever written Kisunla write iClick. And so you're starting to see a dynamic change, especially in areas where there's long drive times.
For example, You know, the fastest uptake that we have is on the West Coast where you're seeing really a lot of space and geography, and you're also seeing the convenience factor happen as well. And so with that being said, I think that this year right now it's outpacing what our plans were, it is early days. And as you look at next year, I think that we're going to see that sub-Q has now become a really tremendous option for both patients and physicians.
And for physicians to write it that have never written an AAT before is a very good signal to us that this can be very promising for next year and the years beyond.

**Tim Power (Investor Relations)** [0:47:25]
Thanks, Alicia. Can we go to the next question, please?

**Cynthia (Operator)** [0:47:28]
Your next question comes from the line of Jeff Meacham with Citi.

**Jeff Meacham (Citi)** [0:47:32]
Morning, guys. Thanks for the question. Bigger picture one for Chris. It looks like the return to top line growth is durable, lots of interest in the pipeline.
I guess the question is when you think about capital deployment, you know, what would you prioritize? Is it further expanding both Argonne development, for example, more commercial investments in Cythovry or in Paveli, or is it staying aggressive in BD? Just want to get kind of the internal to external balance from you looking forward.

**Christopher A. Viehbacher (CEO)** [0:48:04]
Yeah, thanks. Well, there's no question that, you know, obviously we have to wait until the clinical trial results, but we are looking at these 10 Phase III launches or five NME launches.
Now, part of the rationale, remember, for acquiring a PELIS was already to acquire a commercial team for Fels-Artemab. Now, that doesn't mean we wouldn't want to expand that further, but it's not going to be a, you know, we're starting from scratch type investment in that space. Lupus, I would suspect, is going to need a lot of investment, a lot of education. Zorvinursin, I think, is really a limited population that's going to look a lot more like a rare disease, and Salon Erson also comes in behind Spinraza.
So as we grow the business, I think our objective is clearly to invest not only in commercial but continued investment in R &D. But equally, I think investors have waited a long time for us to grow, and so we're going to be very mindful of different ratios and the amount of investment versus growing our bottom line. But I think we can manage all of that, actually. So we will invest in our continued success for sure. In terms of external, as I was saying earlier, I think we're really focused on the early stage.
This is the most capital-efficient time to introduce new assets to a company. I really always hated having to go buy assets in later stage because there's still a fair amount of risk associated with that. And I think if we have reasonable success with the pipeline, again, we have to wait and see the results, but there's a good potential that the company can just grow now for the foreseeable future. So that's why we're focused on really growth into the next decade.
and there we have the time to grow the assets and so we're looking a lot at DC to Phase 1B I would say is probably our sweet spot. We've been fairly intentional about M &A over the last three years. We have looked at everything and filtered through everything. We're not being as intentional now but we can still be opportunistic if we see something that would add to one of our existing franchises. One of the things I'm quite mindful of is distraction.
You know we have dramatically changing Biogen. You know four years ago we really only called on neurologists and and now you know our regional teams are looking at retina specialists, nephrologists, transplant nephrologists. With lupus, it'll be, you know, we're looking at a dermatologist and rheumatologist. We're looking at potentially epileptologists with zorovinursin. So that's, you know, we really expanded the whole commercial organization. We are busy recruiting an awful lot of capability. Out of the top 150 executives in the company, you know, about half have joined in the last three years so all of that is is a tremendous amount of change and i think we really want to be able to digest that change um and really uh take advantage of
the opportunities that are in front of us and and and be careful about overextending ourselves so so that's how i'm thinking about it

**Tim Power (Investor Relations)** [0:51:55]
let's go to our next question

**Cynthia (Operator)** [0:51:58]
Your next question comes from the line of David Anselm with Piper Sandler.

**David Anselm (Piper Sandler)** [0:52:04]
Thanks. So I wanted to ask a commercialization question on lidofilumab, and I realize I might be putting the cart before the horse here given the data readouts, but I wanted to get your thoughts on how you're sizing the CLE opportunity relative to the SLE opportunity, bearing in mind that many patients with cutaneous disease have systemic disease, although there's no therapies approved for cutaneous disease or it's a much, there's a dearth of treatment options, of course, there.
So how are you thinking about sizing in terms of the two opportunities and how distinct do you look at these two opportunities? Thank you.

**Alicia Alimo (Executive)** [0:52:49]
Hi, thank you. This is Alicia. I think first of all, the way in which we view these is they are separate opportunities. So if you look at CLE, there's 250,000 patients that have CLE only, where when you look at SLE, there's 300,000 patients that have SLE only. There's 50,000 patients that have both.
So CLE in total is 300,000 patients. When you also look at CLE, the way the team has phrased it, CLE is life-changing for a patient. In SLE, it is life-ending. That means that they are very different markets. In CLE, less than 5 % are actually treated, which is different than SLE, which you know is around 30%. There is a split across rheumatology and dermatology with only a third of these patients being managed by dermatology.
And what ends up happening with the patients is that specialists will refer to each other. So the patients then get left waiting while the damage continues to go because they sort of get stuck in the middle. If you talk to a physician for CLE, what they want to happen for a product, so if they were to prescribe, because right now they don't prescribe the biologics for this disease, they really want to make sure the drug works, it's safe, and fairly easy to use.
They don't want a lot of monitoring, and they want to be able to access it very quickly, which means patient services becomes quite important in this disease state. The patient goal is they just want some sort of visible improvement. So this will be before they have a permanent scarring, before they have hair loss, or before there is really a major disfigurement, especially of their face. So in this area, our push is more to get the dermatologist to treat, where you know with SLE, rheumatologists are already treating.
So we want to make sure dermatologists have the empowerment and that they treat early and urgent. And we need to simplify this diagnosis for them so that patients aren't experiencing any of these horrible, irreversible damage that they talk about so much. And then accelerate the adoption of the higher efficacy treatments. So what we don't want to see in dermatology like what you see in rheumatology is them waiting. And we believe, because DERMS already prescribe biologics in other parts of their business, that they will end up picking up these products at a fairly good clip once they understand how they work, how to access them, and once we're on formularies.
So we do look at it a little bit differently than we look at SLE.

**Tim Power (Investor Relations)** [0:55:34]
Thanks, Alicia. Let's go to the next question, please.

**Cynthia (Operator)** [0:55:38]
Your next question comes from the line of Daniel Brill with Truist Securities.

**Daniel Brill (Truist Securities)** [0:55:43]
Hi, guys. Good morning. Thanks so much for the question. Maybe I'll actually ask one on iGAN. So, with the FDA now open to a one-year eGFR endpoint and the APRIL-BAF agents becoming the standard of care, are you reconsidering Prevail's design, including the two years on placebo?
And then if you do shift to a one-year eGFR endpoint, would the trial still be adequately powered?

**Priya Singal (Executive)** [0:56:10]
Thank you, Daniel. You know, just stepping back, I think we have assessed that while proteinuria remains a very relevant marker of disease activity as well as UPCR, EGFR really provides a more clinically meaningful measure of long-term renal outcomes. So we are actually planning to stay current and ahead by updating our primary endpoint to EGFR to reflect the evolving evidence base and the increasing importance of directly assessing kidney function in IAM.
So we're already embarking on this change. We think that the change is going to align the program with the current treatment landscape as well as regulatory expectations and will allow us to more clearly characterize the potential benefit of fuzzatomab. But in addition, I would say that we continue to hear and get reinforcement on the fact that the drug holiday and ability for patients to be off drug while staying in remission is very important. So this continues to be a very important differentiator for felzatumab and IGAN.
So we'll continue to keep both those aspects in mind as we reflect these updates.

**Tim Power (Investor Relations)** [0:57:24]
Thanks, Priya. Let's go to the next question, please, Cynthia.

**Cynthia (Operator)** [0:57:28]
Your next question comes from the line of Mohit Bonsal with Wells Fargo.

**Analyst** [0:57:33]
Great. Thank you very much for taking my question. Congrats on all the progress. Just trying to understand the guidance a little bit here. If I do like a plain math of like 5 % growth, assuming that's what you mean by mid-single-digit growth, and subtract the past nine months of sales, it seems like you are modeling quite a lot of drops sequentially in fourth quarter versus third quarter.
I get about $30 million is talking, but what are we missing? because it seems like a lot of drop from third quarter to fourth quarter. So, we'll have to understand how you are thinking about it.

**Robin Kramer (CFO)** [0:58:12]
Yes. So, thank you for the question. So, when you look at the Q3 results, as I noted in my remarks, on a top-line basis, we noted that we did have this significant tailwind, as Alicia pointed out, with the conversion rate on SPIN HD.
And so we saw a pull forward of conversions that we expected to occur in Q4 to the Q3 timeframe, as well as some of the inventory dynamics I mentioned as it related to SKYCLARYS and some of our other products. So from a top line perspective, we had this positive pull forward. The guidance update and where we've landed is a factor. You might recall in the last earnings call, we did raise our guidance. In the current quarter, we're lifting the lower end of the guidance range, and that's driven primarily by the Apellis integration and the success we've had there, both the top line performance as well as the earlier capture of the synergies on the expense side.

**Tim Power (Investor Relations)** [0:59:15]
Thanks, Robin. Let's go to the next question, please.

**Cynthia (Operator)** [0:59:18]
Your next question comes from the line of Andrew Tai with Jeffries.

**Andrew Tai (Jefferies)** [0:59:22]
Hey, good morning. So, on SLE, if litofilumab and DAPI both succeeded, can you remind us how these two drugs would be positioned relative to each other as well as the competing drugs out there and what would be the reasons to believe why either drug could be used as a first-line therapy ahead of standard of care?

**Alicia Alimo (Executive)** [0:59:43]
Hi, thank you. This is Alicia and I'll take that answer. So, you know, we're working on positioning right now for both of these products, especially if we are fortunate to have both of them be approved, which, by the way, gives us two shots on goal for SLE, which we also find critically important. We also believe that they may offer, you know, some differentiation. So, for example, we do know that DAPI has shown improvement in fatigue, and we know one of the major complaints from SLE patients is fatigue.
Now, when it comes to first line, you know, in SLE, there's going to be a lot of competitors, but depending on how the data reads out, I believe that the way that you will have a success in lupus, it will be directly correlated to how you address the barriers that these physicians and patients are going up against. So it will also be data dependent. However, what the current organizations have not been able to do is actually address barriers on why they're waiting, as Chris mentioned, waiting on prescribing products.
The patients haven't been activated to go in and ask for these products. And so I also think with the commercial powerhouse that Biogen has been able to create over the last seven years with all of the seven launches that we've had, we also believe that the commercialization, how you market the product, will become just as important. And so it remains to be seen, but with two shots on goal, I think we're going to be able to compete to win pretty well.
And here again, I think Biogen has a lot of experience. We've had multiple products in the MS portfolio, for instance, and have been able to find exactly which patient benefits from which product at the right time. So I think that will transfer to lupus as well if we are fortunate enough to have both of those products.

**Tim Power (Investor Relations)** [1:01:31]
Thanks, Chris. Let's go to our last question, please.

**Cynthia (Operator)** [1:01:34]
Your last question comes from the line of Mark Goodman with Learink Partners.

**Mark Goodman (Leerink Partners)** [1:01:41]
Yes, good morning. I heard your comment on inventory with SKYCLARYS, but could you give us a little more detail just on what you meant by growth? How much growth are we seeing in patients in the U .S.? And just give us a little bit of the dynamic going on overseas because it's kind of country by country and what's come on and what's still to come on, what's growing, what's been reimbursed. Just give us a little more detail there.
Thanks.

**Alicia Alimo (Executive)** [1:02:02]
Hi, thank you. That's Alicia. I'll take the first part of the question, especially around the U .S. You know, we're encouraged by our 2026 performance with SKYCLARYS, especially as we continue to grow year over year. We do believe we will continue that growth moving forward. There's a couple dynamics at play, especially in our organization. I think first and foremost, the patient-finding tools that we have now and the AI predicting where these patients are and the way in which the teams collaborate to find them has really gotten to a level, I think, of one of the most efficient models that I have seen.
And so they've done a very good job of finding those patients and getting them on product. The other thing that the team has done very well is in the beginning, we had a very high disc con rate off of SKYCLARYS. That is now normalized at a much lower percentage than what we've had before. And we're seeing that discons continue to sort of stay flat as we move through the rest of the year. So we believe that we will continue to grow year over year.
but more importantly, the pediatric expansion represents the next meaningful opportunity for us for a growth inflection as we look ahead.

**Robin Kramer (CFO)** [1:03:10]
And this is Rob, and I'll speak to the ex-US dynamics. We expect from a demand perspective that the growth, both the remainder of this year and into next year, is primarily going to be coming from the continued expansion of SKYCLARYS globally. We continue to launch in new jurisdictions, including the recent approval in Brazil. And so that's where the future growth from a demand perspective is focused on.

**Tim Power (Investor Relations)** [1:03:39]
Thanks, Robin, and thanks everybody for your participation today. If you've got more questions, just reach out to us at the IR team here at Biogen. This concludes today's call. Thank you for your participation. You may now disconnect.
